FDA Approves Vetoquinol’s Felpreva for Quarterly Feline Parasite Control

Vetoquinol has received FDA approval for Felpreva, a prescription-only, broad-spectrum topical parasiticide for cats. The treatment is designed for administration just four times per year, offering veterinarians and cat owners a less frequent parasite-control option.
simba, nature, cat, portrait, cat photography, animals, pet, animal, domestic cat
Photo by jscreativelab on Pixabay
  • The FDA has approved Vetoquinol’s Felpreva for use in cats in the United States.
  • Felpreva is a prescription-only, broad-spectrum topical parasiticide developed exclusively for feline use.
  • The product is designed to be administered four times annually, reducing the frequency of applications.
  • Felpreva has been available in the European Union since its launch in 2022.
  • The approval expands Vetoquinol’s feline parasiticide portfolio into the U.S. market.

Vetoquinol has announced U.S. Food and Drug Administration (FDA) approval of Felpreva, a broad-spectrum topical parasiticide developed specifically for cats. The prescription-only product is designed to provide parasite treatment and control with just four applications per year.

The approval introduces another option for U.S. veterinarians seeking to simplify feline parasite management while reducing the number of treatments cat owners need to administer.

Quarterly Dosing Designed to Simplify Parasite Control

Felpreva’s quarterly application schedule is a central feature of the product. With four topical doses annually, the treatment is intended to make parasite control more manageable for cat owners and veterinary teams.

“We are excited to bring Felpreva™ to U.S. veterinarians and cat owners,” said Matthieu Frechin, chairman and CEO of Vetoquinol. “Felpreva™ takes the complexity out of parasite control for both veterinarians and cat owners by providing a straightforward solution: fewer applications with broad-spectrum treatment and control.”

Felpreva is available by veterinary prescription only and is intended exclusively for cats. The company’s announcement did not specify the product’s approved parasite indications or anticipated U.S. commercial launch date.

Builds on European Market Experience

Felpreva was first introduced in the European Union in 2022, giving Vetoquinol several years of commercial experience with the product before its U.S. regulatory approval.

The U.S. authorization represents an expansion of the company’s feline parasiticide portfolio into another major animal health market.

Headquartered in France, Vetoquinol develops and markets veterinary medicines and other animal health products for companion animals and livestock. The company operates across Europe, the Americas and Asia-Pacific and reported 2,526 employees as of June 30, 2026.

Information sourced from Vetoquinol’s press release.

Never Miss an Animal Health Story

Sign up for free to receive the latest veterinary news, product announcements, and industry developments.